CSL shares (ASX: CSL) jumped 7.15% on Wednesday, before having a steadier day on Thursday in closing at A$127.93, to sit 12% higher week to date. The latest price action comes on news that CSL will undertake clinical trials for it’s Horizon 2 process, and growing anticipation of the company’s 18 August full-year result triggered a wave of buying in one of the ASX 200’s most bruised stocks.
Volume of 2.84 million shares during the mid-week jump underscored the intensity of the move (2.84x ADV), which pushed the CSL share price above the upper edge of its recent trading range of A$125, and marked a sharp reversal from the 52% collapse that defined its fiscal 2026. The trials will confirm the safety of immunoglobulin produced using the process, and follow engagement with the FDA and EMA.
After a year in which guidance downgrades, leadership flux, and the Vifor acquisition debacle hammered confidence, recent strength suggests markets are willing to lean into the stock again, at least on a short-term basis. The healthcare sector more broadly was the best performer on the day in a which all sectors closed green.
What Else Is Happening At CSL
An earlier catalyst arrived over the weekend, when CSL announced positive Phase 3b top-line results for ANDEMBRY, its subcutaneous therapy for hereditary angioedema, in children aged 2 to 11. The trial showed favorable safety and tolerability, with most pediatric patients remaining attack-free over 12 months. CSL plans to file for expanded pediatric indications in the first half of its fiscal year, a tangible win for the Behring division and a reminder that the company’s rare-disease franchise still generates meaningful growth optionality even as near-term numbers disappoint.
The timing of the data release matters. CSL’s 18 August result looms as a pivotal moment, when the market will finally see the full scope of the company’s US$5 billion impairment program, the progress of its transformation plan targeting US$500 million to US$550 million in annual savings by fiscal 2028, and any updates on CEO succession and the planned Seqirus demerger.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Expectations have been heavily reset: fiscal 2026 revenue guidance was cut to around US$15.2 billion in May, with US immunoglobulin revenue down roughly US$300 million, albumin sales in China off US$200 million, and additional headwinds from conflict and product competition. Underlying net profit after tax for the half-year to December fell 7%, and the company has openly described the Vifor acquisition as an expensive mistake, with large intangibles impairments and under-utilized assets weighing on the balance sheet.
Long-only value managers who stayed on the sidelines during the worst of the sell-off may be adding exposure now that the bar is low, while short-covering ahead of an event-heavy August could be amplifying the technical momentum. The ANDEMBRY data provides a narrative hook: CSL is not just a plasma and albumin story under pressure, but a diversified biotech with high-value intellectual property and ongoing clinical catalysts.
The Technical Setup
The technical setup supports the idea of a squeeze rather than a steady grind. The stock closed above its upper Bollinger Band of A$127.10, with the band width at 10.25%, pointing to a short-term volatility spike and range expansion after a prolonged period of weakness.
The ADX reading of 25.75 indicates trend strength is still present, though the falling ADX suggests the prior downtrend is losing intensity and the move may be transitioning into a basing or counter-trend rally phase. The CCI at -61.23 sits in neutral territory but is recovering from a downside stretch, consistent with rotation from washed-out to constructive rather than a fresh overbought spike.
The average price target on CSL shares sits at A$139.10, ~9.2% above today’s close, a level that suggests the Street has not fully capitulated despite the share-price damage.
What Next?
The bear case remains formidable. The Vifor overhang is not resolved: the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking EU marketing authorization for TAVNEOS, adding to the list of Vifor-related disappointments. Plasma pricing pressure in the US and policy shifts in China continue to hurt immunoglobulin and albumin revenue, and interim CEO Gordon Naylor has acknowledged that financial benefits from the transformation program will take longer than previously anticipated to materialize.
CSL’s recent track record of earnings shocks has created something of a trust deficit, and recent strength appears tactical rather than a conviction shift, at least until the company proves it can hit fiscal 2026 and 2027 numbers.
Still, the market is signaling that the risk-reward calculus has shifted. After one of the worst years in CSL’s history, the combination of a high-profile clinical win, heavily reset expectations, and an imminent catalyst is enough to bring buyers back to the table. Whether that translates into a sustained recovery or simply a relief rally ahead of another leg lower will depend on what CSL delivers in three weeks’ time.
Bull Case:
- ANDEMBRY pediatric win validates rare-disease pipeline and growth optionality beyond plasma.
- Expectations heavily reset after 52% fall; low bar for positive surprise.
- Consensus targets 9.2% above current price; room for re-rating if August delivers.
Bear Case:
- US$5 billion impairment and Vifor overhang unresolved; TAVNEOS EU revocation adds pressure.
- Plasma and China albumin headwinds persist; transformation benefits delayed.
- Trust deficit from repeated earnings shocks; tactical rally may fade post-result.
